Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2017.6420

OL-0-0-6420

Articles

Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-associated advanced hepatocellular carcinoma

Hong

Ying-Fen

1 * Chen

Zhan-Hong

1 2 * Wei

1 * Ma

Xiao-Kun

1 Li

Xing

1 Wen

Jing-Yun

1 Wang

Tian-Tian

1 Cai

Xiu-Rong

1 Wu

Dong-Hao

1 Chen

Jie

1 Ruan

Dan-Yun

1 Lin

Ze-Xiao

1 Lin

1 Dong

Min

1 Wu

Xiang-Yuan

1Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Giangdong 510630, P.R. China 2Department of Medical Oncology of Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China

Correspondence to: Dr Xiang-Yuan Wu or Dr Zhan-Hong Chen, Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, P.R. China, E-mail: wuxiangy@mail.sysu.edu.cn, E-mail: sumszhanhong@163.com *

Contributed equally

08 2017

19 06 2017

14 2 2089 2096 12052016 13042017

2017

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The inflammatory microenvironment serves an important function in the progression of hepatocellular carcinoma (HCC). Peripheral blood lymphocyte-to-monocyte ratio (LMR), as a novel inflammatory biomarker combining an estimate of host immune homeostasis with the tumor microenvironment, has been identified to be a predictor of clinical outcomes in a number of malignancies. The present study aimed at investigating the prognostic value of LMR in patients with hepatitis B virus (HBV)-associated advanced HCC. A total of 174 patients with HBV-associated advanced HCC, without fever or signs of infections, were analyzed. Clinicopathological parameters, including LMR, were evaluated to identify predictors of overall survival time. Univariate and multivariate analysis was performed using Cox's proportional hazards model. A threshold value was determined using a time-dependent receiver operating characteristic curve. Univariate and multivariate analysis identified LMR as an independent prognostic factor in overall survival (OS) time in patients with HBV-associated advanced HCC (P<0.05). The threshold value of LMR was 2.22. All patients were divided into either a low LMR group (≤2.22) or a high LMR group (>2.22). The OS time of the high LMR group was significantly longer compared with the low LMR group (P<0.001). Patients in the high LMR group exhibited a significantly increased 3-month and 6-month OS rate, compared with that of the patients within the low LMR group (P<0.001). An increased level of LMR was significantly associated with the presence of metastasis, ascites and increased tumor size (P<0.01). LMR is an independent prognostic factor of HBV-associated advanced HCC patients and an increased baseline LMR level indicates an improved prognosis.

lymphocyte-to-monocyte ratio inflammation chronic hepatitis B virus infection prognosis advanced hepatocellular carcinoma

Introduction

Hepatocellular carcinoma (HCC) ranks fifth among the primary causes of cancer-associated mortality in males and ninth in females (1). In China, HCC is the most common type of cancer and the highest cause of cancer mortality in males <60 years (2), due to widespread hepatitis B virus (HBV) infection which almost 90% of patients with HCC experience. Hepatitis C virus (HCV) infection, alcoholism and obesity are additional risk factors for HCC in the western world (3). At present, the only treatment for HCC is hepatic resection which is restricted to the patients who have localized lesions arising in non-cirrhotic livers, or in cirrhotic livers with well-preserved hepatic function (4). However, the majority of patients are initially diagnosed with advanced HCC and therefore the majority of patients with HCC are unable to be treated by resection. Despite substantial progress achieved in the treatment for advanced HCC in previous years, including targeted therapy (sorafenib, a kinase inhibitor drug) and interventional therapy, the overall 5-year survival rate remains unsatisfactory. The prognosis and treatment of HCC depends on the tumor stage, the patient's physical status and liver function (4,5). Clinicopathological factors including microvascular invasion, novel extrahepatic lesions and portal vein tumor thrombus (PVTT) have been used to predict survival time in patients with advanced HCC (6,7). However, these aforementioned clinical tumor parameters may only partially explain the prognostic heterogeneity of HCC.

The inflammatory microenvironment serves an important function in the development and progression of HCC. In China, chronic liver inflammation primarily contributes to the development of HCC (8). In addition, the host response in systemic inflammation has been considered to be an independent prognostic factor for patients with HCC (9–12). C-reactive protein (13,14), white blood cell counts, platelet counts (15), neutrophil counts (16) and monocyte counts (17) have been primarily investigated as clinical indicators of inflammation for cancer. Previous studies have indicated that the development of HCC is associated with alterations of peripheral blood white blood cells. The principal alterations include neutrophilia with relative lymphocytopenia or thrombocytosis. White blood cells, along with the cytokines and chemokines secreted, serve a role in the viability, maturation and differentiation of cells within the tumor microenvironment. Peripheral blood lymphocyte-to-monocyte ratio (LMR), an indication of lymphocytopenia and an increased monocyte count, has been identified to be a novel inflammatory biomarker. LMR combines an estimate of host immune homeostasis and tumor microenvironment and has been identified as a predictor for clinical outcomes in a variety of malignancies, including breast (18), renal (19,20), lung (21) and colorectal (22) cancer. Recently, a study elucidated that LMR was an independent prognostic factor in patients with HBV-associated HCC following curative resection (23). However, to the best of our knowledge, there have been no studies regarding the prognostic value of LMR in advanced HCC until the present study, which aimed at clarifying the prognostic value of LMR in patients with HBV-associated advanced HCC.

Materials and methods <sec> <title>Patients

The Clinical Ethics Review Board at The Third Affiliated Hospital of Sun Yat-sen University (Guangdong, China) approved the present study, and written informed consent was obtained from the patients or their family members. Medical records of 174 consecutive Chinese patients with HBV-associated advanced HCC presented to The Third Affiliated Hospital of Sun Yat-sen University (Guangdong, China) between September 2008 and June 2010, were reviewed and retrospectively analyzed in the present study. The inclusion criteria of the patients were as follows: i) Patients were diagnosed with advanced HCC. The diagnosis of HCC was confirmed using pathological analysis or the patients met the radiological criteria from The American Association for the Study of Liver Diseases (4), including computed tomography (CT) and magnetic resonance imaging (MRI). Patients with advanced HCC exhibited stage C or D, according to The Barcelona Clinic Liver Cancer Staging for Hepatocellular Carcinoma (BCLC) (24). ii) All the patients had chronic HBV infection and were negative for anti-HCV antibody. iii) Antiviral therapy with oral nucleos(t)ide analogues was recommended for all patients, although the patients did not receive antitumor treatment recommended by the National Comprehensive Cancer Network guidelines (25) including chemotherapy, targeted therapy or locoregional therapies (percutaneous ethanol injection or transarterial chemoembolization). The exclusion criteria of the patients were as follows: i) Patients exhibited a fever or additional manifestations of acute infections; ii) patients exhibited previous or secondary cancers and coexistent hematological disorders; and iii) patients did not possess information required for the present study or lost follow-up within 6 months.

Collection of patient information

Acquisition of patient results from electronic charts was approved by the institutional ethics committee of the Third Affiliated Hospital of Sun Yat-sen University (Guangdong, China). Clinical examination, laboratory studies and imaging studies (CT or MRI) were required for baseline evaluation. Information was collected at the time of the initial diagnosis of advanced HCC. The overall survival (OS) time was calculated between the date of diagnosis and the date of mortality or last contact, for surviving patients.

Demographic information, laboratory results [including routine blood tests, liver function parameters, serum α-fetoprotein (AFP) level], BCLC stage and Karnofsky performance status (26) were retrospectively analyzed from the patients' clinical records. Tumor-associated variables, including maximal tumor diameter, number of tumor nodules and PVTT were obtained from medical image diagnostic results. The peripheral blood absolute lymphocyte count (ALC) and absolute monocyte count (AMC) were derived from the complete blood cell count prior to initiation of treatment, with the LMR calculated by dividing the lymphocyte count by the monocyte count.

Statistical analysis

Fisher's exact test (two-tailed) or χ² test was used to analyze categorical variables, whereas Student's t-test or non-parametric tests were used to analyze continuous variables. Using OS time as the end-point, the optimal threshold value of LMR using receiver operating curve (ROC) analysis was obtained when the Youden index (sensitivity + specificity-1) (27) was maximal. Subsequently, patients with an LMR greater than the threshold value were classified as high LMR (HLMR) and the remaining patients were classified as low LMR (LLMR). Survival curves for the two groups were plotted using the Kaplan-Meier estimator method and the significance was analyzed using the log-rank test. Significant factors for OS time in Cox's univariate analysis were assessed using Cox's proportional hazards model (forward method) to determine the independent prognostic predictors. Associations between LMR levels and baseline characteristics, including clinicopathological features, were analyzed using χ² test. All statistical analysis was conducted using SPSS (version 20.0; IBM Corp., Armonk, NY, USA) and Stata software (version 12.0; StataCorp LP, College Station, TX, USA). For all tests, P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Patient characteristics

In the present study, of the 174 patients with HBV-associated advanced HCC, 157 (90.2%) were male and the mean age was 55 years (range, 19–85 years). The mean counts of white blood cells, neutrophils, ALC, AMC and platelets were 6.84×10⁹ cells/l [range, (1.84–25.09)x10⁹ cells/l], 4.89×10⁹ cells/l [range, (1.11–22.44)x10⁹ cells/l], 1.23×10⁹ cells/l [range, (0.32–4.18)x10⁹ cells/l], 0.60×10⁹ cells/l [range, (0.08–3.85)x10⁹ cells/l] and 156.3 cells/l [range, (4–503)x10⁹ cells/l], respectively. The median LMR was 2.57 (range, 0.39–7.0). A total of 53 (30.5%) patients with lymph node metastasis and 36 (20.7%) patients with initial distant metastasis were recorded from newly diagnosed patients. According to BCLC staging criteria, the number of patients with stage C and D advanced HCC was 95 (54.6%) and 79 (45.4%), respectively. Of the patients included in the present study, 152 (87.4%) patients succumbed to cancer-associated disease. The 3-month and 6-month mortality rates were 59.2 and 74.1%, respectively. Additional information for the patients' baseline demographics are presented in Table I.

Independent prognostic factors for overall survival

To identify the optimal peripheral blood inflammatory and immune biomarker for patient prognosis, the impact of leukocyte, neutrophil, ALC, AMC and LMR on survival outcomes was investigated. In the univariate analysis, leukocytes, neutrophils, AMC and LMR were identified to be significant prognostic factors, with P<0.001 for leukocytes, neutrophils and LMR, P=0.04 for AMC and no significant difference indicated for ALC. Additional independent prognostic factors that may be associated with overall survival time included age, platelets, aspartate transaminase (AST), AFP, ascites, tumor number, tumor size and PVTT (P<0.05). The aforementioned factors identifying statistical significance were assessed using Cox's multivariate regression analysis to determine the significance of independent factors. In the multivariate analysis, LMR [hazard ratio (HR), 0.858; 95% confidence interval (CI), 0.754–0.976; P=0.020], neutrophil (HR, 1.104; 95% CI, 1.046–1.165; P<0.001), PVTT (HR, 1.984; 95% CI, 1.296–3.037; P<0.001) and AFP >400 g/ml (HR, 1.739; 95% CI, 1.221–2.478; P=0.002) remained independent prognostic predictors (Table II).

Optimal threshold value for LMR

LMR was used as the test variable and the OS time was employed as the state variable for LMR. According to the ROC curve, the optimal threshold value for LMR was 2.22 (sensitivity, 63.1%; specificity, 69.0%) (Fig. 1). Patients were dichotomized into either the HLMR group or LLMR group, on the basis of the optimal threshold value. A total of 86 patients (49.4%) were included in the LLMR group (≤2.22) and 88 patients (50.5%) were included in the HLMR group (>2.22).

Comparison of patients between the HLMR and LLMR groups

To determine the association between LMR and clinicopathological features of patients with HBV-associated advanced HCC, comparisons between the HLMR group and LLMR group were made (Table III). The results indicated that HLMR group exhibited a tendency to present distant metastasis, ascites and a larger tumor size (P<0.01). The LLMR level was significantly associated with increased leukocytes, neutrophils, AMC, ALC, AST, total bilirubin, alkaline phosphatase (P<0.001) and albumin (P=0.045). In the survival analysis, the 3-month and 6-month survival rates of the HLMR group were significantly increased compared with those of the LLMR group (P<0.001). A Kaplan-Meier estimator curve identified that the OS rate was significantly decreased in the LLMR group compared with that of the HLMR group (P<0.001, Fig. 2).

Discussion

HCC has been established as life-threatening disease and it has been reported that majority of patients are initially diagnosed with advanced HCC. Despite the efforts of clinicians to prolong the survival time of patients with advanced HCC, effective therapies are limited. A number of clinicopathological characteristics, including tumor size and thrombosis, have become the primary determinants of existing therapies and predictors of prognosis of patients with HCC. However, these aforementioned factors are far from meeting medical needs.

In 1863, Virchow (28) first proposed the association between inflammation and cancer. Subsequently, a number of studies have indicated the important function of inflammation in early carcinogenesis, development, metastasis and therapeutic response of cancers (29–31). HCC was a typical example of inflammation-associated cancer as the majority of HCC developed in the setting of chronic liver damage and inflammation, particularly in China. Therefore, in the present study, to illustrate the function of LMR in HBV-associated advanced HCC, only patients with HBV infection were included. Pretreatment numbers of peripheral blood cells, including neutrophils, ALC, AMC and platelets, have been suggested to be marked prognostic factors in a number of types of malignancies. Neutrophils, as the largest proportion of leukocytes in human peripheral blood, secrete mediators including cytokines and matrix metalloproteinase-9 to react to cancer (32,33) and alter their phenotype, similar to granulocytic myeloid-derived suppressor cells, allowing them to exhibit distinct characteristics of maturity, tumor cytotoxicity and immune suppression (34). During tumor development, the inflammatory response may cause lymphocytopenia, leading to the inhibition of suppression of tumor progression (35). Macrophages, which are tissue-resident cells that develop from circulating monocytes in local tissues, are reported to influence tumor migration and invasion, and suppress antitumor immunity (36,37). In addition, a number of studies have demonstrated platelet involvement in tumor metastasis. The activation of platelets protect tumor cells from immune elimination by promoting their arrest at the endothelium, thereby supporting the establishment of secondary lesions (38,39).

On the basis of the association between systemic inflammation and carcinoma, increasing numbers of inflammatory markers have been associated with poor prognosis of a variety of types of cancers. Chen et al (40) identified that patients with resectable gastric cancer who exhibited increased preoperative white blood cells and p-leukopenia had a poorer prognosis, compared with those with exhibited lower baseline white blood cells and no p-leukopenia. Kitayama et al (41) revealed that in patients with colorectal cancer, the lymphocyte count was markedly associated with tumor response to neoadjuvant chemoradiotherapy. Peripheral blood LMR, as a novel inflammatory biomarker, has been identified as a predictor of clinical outcome in a number of types of cancer (18–22). In regard to HCC, to the best of our knowledge, only one study has demonstrated an association between LMR and HCC (42). Lin et al (23) identified that preoperative LMR may serve as an independent prognostic factor for patients with HBV-associated HCC undergoing curative resection. However, to the best of our knowledge, the function of LMR in HBV-associated advanced HCC remains unclear.

The present study, to the best of our knowledge, was the first to demonstrate that LMR level was independently associated with OS for patients with advanced HCC. Only patients with HBV-associated HCC who do not exhibit a fever, or any other manifestations of acute infections, were included to avoid potential confounding factors from distinct etiologies, since infection alters blood cell number. The results of the present study identified LMR, but not ALC or AMC, to be an independent predictor of the OS rate in patients with HBV-associated advanced HCC. The aforementioned patients with an LMR ≤2.22 exhibited a decreased 3-month and 6-month survival rate compared with those with an LMR >2.22, which was consistent with previous studies that identified low LMR to be an independent poor prognostic factor (18–23). However, the optimal thresholds for LMR in distinct studies differ, which may be due to the different baseline characteristics, type of malignancy, clinical stages and treatments in each study.

The underlying molecular mechanism which enables LMR to be used as a prognostic factor in cancers remains unknown. Lymphocytes are a key mediator in the antitumor immunity of the host and infiltration into the tumor microenvironment is a prerequisite to an immunological antitumor reaction. ALC may alter along with the antitumor immune reaction (35,43,44). ALC decreased when there was an insufficient immunological reaction to the tumor, thus promoting tumor progression and metastasis (45). Although, in the present study, ALC was not identified as a significant factor for the OS rates in patients with advanced HCC, ALC exhibited an antitumor effect. In addition to the quantity of lyphocytes, the phenotype and subset composition may change; however, additional studies are required to determine the underlying molecular mechanism (46–48). As a component of the tumor microenvironment, monocytes serve a markedly active function in tumor development, progression and metastasis (30,49). Inflammation activates the mobilization of monocytes from the bone marrow to the peripheral blood (50) and the differentiation of monocytes into tumor-associated macrophages (TAMs) following recruitment into tumor tissue (51,52), suppressing adaptive immunity and exerting protumoral functions, promoting tumor cell invasion, metastasis and angiogenesis (36,51). The circulating level of monocytes in the peripheral blood is reported to reflect the formation and/or presence of TAMs (45). Therefore, an increased level of monocytes reflects a high tumor burden in patients with cancer (53–55). However, in the present study, AMC was not considered a prognostic factor for the OS rate using multivariate analysis. It is hypothesized that ALC or AMC alone may not explain the effect of inflammation on patients with HBV-associated advanced HCC.

As aforementioned, LMR reflects the interaction between the immune status of the host and the tumor microenvironment. In the present study, the combination of ALC and AMC, compared with ALC and AMC alone, enabled LMR to be an improved predictor of OS rate in patients with HBV-associated advanced HCC, which means that decreased ALC and increased AMC simultaneously reflect the essence of the disease. Decreased LMR is associated with a poorer prognosis. A previous study demonstrated that low LMR may be considered as an independent biomarker for predicting mortality in patients with HBV-related liver cirrhosis (56), which supports the predictive value of LMR identified in the present study, as the majority of HBV-associated advanced HCC developed from liver cirrhosis. Additionally, decreased LMR was markedly associated with a number of clinicopathological characteristics, including distant metastasis, tumor size and ascites, which may reflect either higher tumor burden or a more prolonged chronic inflammatory process, indicating poor prognosis.

LMR is a readily available and low-cost objective marker of systemic inflammation and may be obtained from routine blood testing. Therefore, LMR may be used for prognostic stratification of patients with HBV-associated advanced HCC and may be a potential criterion for patient selection in clinical trials.

However, the present study had limitations. First, it is a retrospective study, the number of patients involved was small and patients were restricted to be from a single center. Secondly, LMR is a non-specific parameter of inflammation and the results may be influenced by the presence of other systemic diseases. Thirdly, the results of the present study were limited to patients with HBV-associated advanced HCC. Additional etiologies of HCC, including HCV and alcohol, require study. Finally, the heterogeneity of patients with advanced HCC includes the distinctions between metastatic sites, which may bias the results. Additional large-scale prospective studies and standard investigations are required to validate the results of the present study.

The present study, to the best of our knowledge, was the first study to analyze the prognosis of patients with HBV-associated advanced HCC on the basis of a novel biomarker, LMR. LMR was identified to be an independent prognostic factor of patients with HBV-associated advanced HCC with increased baseline LMR levels indicating an improved prognosis. A prospective and well-designed study of LMR with larger cohorts is warranted for further validation.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant nos. 31600710 and 81372374), the Natural Science Foundation of Guangdong (grant nos. 2014A030313146 and 2016A030313302) and Project on the Integration of Industry, Education and Research of Guangdong Province (grant no. 2012B091100460)

References 1

Siegel

Miller

Jemal

Cancer statistics, 2015

CA Cancer J Clin655292015

10.3322/caac.21254

25559415

Chen

Zheng

Baade

Zhang

Zeng

Bray

Jemal

Cancer statistics in China, 2015

CA Cancer J Clin661151322016

10.3322/caac.21338

26808342

Yuan

Govindarajan

Arakawa

Synergism of alcohol, diabetes and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S

Cancer101100910172014

10.1002/cncr.20427

Bruix

Sherman

Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma

Hepatology42120812362005

10.1002/hep.20933

16250051

Wang

Cong

Shi

Song

Chen

Efficacy of sorafenib for advanced hepatocellular carcinoma and prognostic factors

Hepatogastroenterology619549572014

10.1016/S0016-5085(14)63473-9

26158148

Ogasawara

Chiba

Ooka

Suzuki

Kanogawa

Saito

Motoyama

Tawada

Kanai

Yokosuka

Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib

Invest New Drugs342552602016

10.1007/s10637-016-0323-1

26769245

Hong

Chen

Dong

Wei

Wang

Ruan

Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma

Tumour Biol37526552732015

10.1007/s13277-015-4366-2

26561464

Sherman

Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis

Semin Liver Dis303162010

10.1055/s-0030-1247128

20175029

Bugada

Allegri

Lavand'homme

De Kock

Fanelli

Inflammation-based scores: A new method for patient-targeted strategies and improved perioperative outcome in cancer patients

Biomed Res Int20141424252014

10.1155/2014/142425

24877056

Deng

Liu

Yue

Ying

Pan

Sun

Chen

Wang

Gao

Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model

J Transl Med13662015

10.1186/s12967-015-0409-0

25885254

Shiels

Katki

Hildesheim

Pfeiffer

Engels

Williams

Kemp

Caporaso

Pinto

Chaturvedi

Circulating inflammation markers, risk of lung cancer, and utility for risk stratification

J Natl Cancer Inst107djv1992015

10.1093/jnci/djv199

26220734

Morrison

Laukkanen

Ronkainen

Kurl

Kauhanen

Toriola

Inflammatory biomarker score and cancer: A population-based prospective cohort study

BMC Cancer16802016

10.1186/s12885-016-2115-6

26860264

Fang

Wang

Sui

Liu

Ross

Gershenwald

Cormier

Royal

Lucci

Schacherer

C-reactive protein as a marker of melanoma progression

J Clin Oncol33138913962015

10.1200/JCO.2014.58.0209

25779565

Aleksandrova

Boeing

Nöthlings

Jenab

Fedirko

Kaaks

Lukanova

Trichopoulou

Trichopoulos

Boffetta

Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer

Hepatology608588712014

10.1002/hep.27016

24443059

Schumacher

Strilic

Sivaraj

Wettschureck

Offermanns

Platelet-derived nucleotides promote tumor-cell transendothelialmigration and metastasis via p2y2 receptor

Cancer Cell241301372013

10.1016/j.ccr.2013.05.008

23810565

Grosse-Steffen

Giese

Longerich

Schirmacher

Hansch

Gaida

Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: The role of neutrophils and neutrophil-derived elastase

Clin Dev Immunol20127207682012

10.1155/2012/720768

23227088

Ren

Zhao

Guo

Chen

Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation

Tumor Biol37897389882016

10.1007/s13277-015-4758-3

Jia

Yang

Zhang

Chen

The peripheral blood Neutrophil-to-Lymphocyte ratio is superior to the Lymphocyte-to-Monocyte ratio for predicting the long-term survival of triple-negative breast cancer patients

PLoS One10e01430612015

10.1371/journal.pone.0143061

26580962

Chang

Zhou

Liu

Yang

Lin

Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma

Tumor Biol37461346202016

10.1007/s13277-015-4300-7

Chang

Zhu

Yang

Lin

Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma

Br J Cancer1136266332015

10.1038/bjc.2015.241

26135896

Chen

Lai

Chang

Chao

Tseng

Fang

Wang

Chung

Wang

Baseline and trend of Lymphocyte-to-Monocyte ratio as prognostic factors in epidermal growth factor receptor mutant non-small cell lung cancer patients treated with first-line epidermal growth factor tyrosine kinase inhibitors

PLoS One10e01362522015

10.1371/journal.pone.0136252

26313661

Shibutani

Maeda

Nagahara

Ohtani

Sakurai

Yamazoe

Kimura

Toyokawa

Amano

Tanaka

Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer

World J Gastroenterol21996699732015

10.3748/wjg.v21.i34.9966

26379401

Lin

Ruan

Chen

Wang

Lin

Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection

World J Gastroenterol2110898109062015

10.3748/wjg.v21.i38.10898

26478681

Llovet

Brú

Bruix

Prognosis of hepatocellular carcinoma: The BCLC staging classification

Semin Liver Dis193293381999

10.1055/s-2007-1007122

10518312

National Comprehensive Cancer Network. NCCN Guidelines Version 2.2105 Hepatocellular Carcinoma

Schag

Heinrich

Ganz

Karnofsky performance status revisited: Reliability, validity, and guidelines

J Clin Oncol21871931984

10.1200/JCO.1984.2.3.187

6699671

Fluss

Faraggi

Reiser

Estimation of the Youden Index and its associated cutoff point

Biom J474584722005

10.1002/bimj.200410135

16161804

Keibel

Singh

Sharma

Inflammation, microenvironment, and the immune system in cancer progression

Curr Pharm Des15194919552009

10.2174/138161209788453167

19519435

Balkwill

Mantovani

Inflammation and cancer: Back to Virchow?

Lancet3575395452001

10.1016/S0140-6736(00)04046-0

11229684

Mantovani

Allavena

Sica

Balkwill

Cancer-related inflammation

Nature4544364442008

10.1038/nature07205

18650914

Wang

Niu

Zhu

Sun

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

Cancer Lett2951101232015

10.1016/j.canlet.2010.02.019

Kuang

Zhao

Peng

Wang

Yin

Zheng

Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma

J Hepatol549489552011

10.1016/j.jhep.2010.08.041

21145847

Lee

Vansaun

Shim

Matrisian

Gorden

Increased metastases are associated with inflammation and matrix metalloproteinase-9 activity at incision sites in a murine model of peritoneal dissemination of colorectal cancer

J Surg Res1802522592013

10.1016/j.jss.2012.04.074

22763216

Mishalian

Granot

Fridlender

The diversity of circulating neutrophils in cancer

Immunobiology22282882017

10.1016/j.imbio.2016.02.001

26874580

Dunn

Old

Schreiber

The immunobiology of cancer immunosurveillance and immunoediting

Immunity211371482004

10.1016/j.immuni.2004.07.017

15308095

Condeelis

Pollard

Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis

Cell1242632662006

10.1016/j.cell.2006.01.007

16439202

Leek

Harris

Tumor-associated macrophages in breast cancer

J Mammary Gland Biol Neoplasia71771892002

10.1023/A:1020304003704

12463738

Gay

Felding-Habermann

Contribution of platelets to tumour metastasis

Nat Rev Cancer111231342011

10.1038/nrc3004

21258396

Buergy

Wenz

Groden

Brockmann

Tumor-platelet interaction in solid tumors

Int J Cancer130274727602012

10.1002/ijc.27441

22261860

Chen

Qian

Pei

Zhou

Røe

Zhu

Qian

Zhou

Prognostic value of perioperative leukocyte count in resectable gastric cancer

World J Gastroenterol22281828272016

10.3748/wjg.v22.i9.2818

26973420

Kitayama

Yasuda

Kawai

Sunami

Nagawa

Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer

Radiat Oncol5472010

10.1186/1748-717X-5-47

20525293

Chen

Gao

Zhang

Xie

Zhang

Prognostic role of lymphocyte to monocyte ratio for patients with cancer: Evidence from a systematic review and meta-analysis

Oncotarget731926319422016

26942464

Hoffmann

Dworacki

Tsukihiro

Meidenbauer

Gooding

Johnson

Whiteside

Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance

Clin Cancer Res8255325622002

12171883

Rabinowich

Cohen

Bruderman

Steiner

Klajman

Functional analysis of mononuclear cells infiltrating into tumors: Lysis of autologous human tumor cells by cultured infiltrating lymphocytes

Cancer Res471731771987

3491673

Stotz

Pichler

Absenger

Szkandera

Arminger

Schaberl-Moser

Samonigg

Stojakovic

Gerger

The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer

Br J Cancer1104354402014

10.1038/bjc.2013.785

24357796

Unitt

Marshall

Gelson

Rushbrook

Davies

Vowler

Morris

Coleman

Alexander

Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation

J Hepatol452462532006

10.1016/j.jhep.2005.12.027

16580084

Zikos

Donnenberg

Landreneau

Luketich

Donnenberg

Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in nonsmall cell lung cancer

Cancer Immunol Immunother608198272011

10.1007/s00262-011-0996-4

21373990

Gao

Qiu

Fan

Zhou

Wang

Xiao

Tang

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection

J Clin Oncol25258625932007

10.1200/JCO.2006.09.4565

17577038

Evani

Prabhu

Gnanaruban

Finol

Ramasubramanian

Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow

FASEB J27301730292013

10.1096/fj.12-224824

23616566

Shi

Pamer

Monocyte recruitment during infection and inflammation

Nat Rev Immunol117627742011

10.1038/nri3070

21984070

Pollard

Tumour-educated macrophages promote tumour progression and metastasis

Nat Rev Cancer471782004

10.1038/nrc1256

14708027

Hagemann

Lawrence

Investigating macrophage and malign interactions in vitro

Methods Mol Biol5123253322009

10.1007/978-1-60327-530-9_18

19347286

Tadmor

Does monocyte count have prognostic significance in cancer?

Leuk Res37119311942013

10.1016/j.leukres.2013.07.035

23953915

Sasaki

Iwashita

Shibata

Matsumoto

Ohta

Kitano

Prognostic value of preoperative peripheral blood monocyte count inpatients with hepatocellular carcinoma

Surgery1397557642006

10.1016/j.surg.2005.10.009

16782430

Lin

Jiang

Peng

Xiao

Liu

Xia

Prognostic significance of the peripheral blood absolute monocyte count inpatients with locally advanced or metastatic hepatocellular carcinoma receiving systemic chemotherapy

Asian Pac J Cancer Prev15638763902014

10.7314/APJCP.2014.15.15.6387

25124630

Zhang

Feng

Zhao

Zhang

Feng

Yang

Association between lymphocyte-to-monocyte ratio (LMR) and the mortality of HBV-related liver cirrhosis: A retrospective cohort study

BMJ Open5e0080332015

10.1136/bmjopen-2015-008033

26297362

Figure 1.

ROC curve assessing the threshold value of LMR for survival analysis in patients. The optimal threshold value of LMR was 2.22, determined using ROC curves, and the area under curve was 0.686 (95% confidence interval, 0.611–0.754; P<0.001) with a sensitivity and specificity of 63.1 and 69.0%, respectively. ROC, receiver operating characteristic; LMR, lymphocyte-to-monocyte ratio.

Figure 2.

Overall survival curves of 174 patients with hepatitis B virus-associated advanced hepatocellular carcinoma. Kaplan-Meier estimator survival curves demonstrated that patients with LMR ≤2.22 had decreased overall survival rates, compared with those with LMR >2.22 (P<0.001, log-rank). LMR, lymphocyte-to-monocyte ratio.

Table I.

Baseline demographics of all patients included in the present study.

Characteristic	Patients (n=174)
Sex
Male	90.2% (157/174)
Female	9.8% (17/174)
Age, years	55 (19–85)
Ascites	66.1% (115/174)
Encephalopathy	2.9% (5/174)
Karnofsky performance status	60 (20–90)
Laboratory parameters
Leukocytes, ×10⁹ cells/l	6.84 (1.84–25.09)
Neutrophils, ×10⁹ cells/l	4.89 (1.11–22.44)
ALC, ×10⁹ cells/l	1.23 (0.32–4.18)
AMC, ×10⁹ cells/l	0.60 (0.08–3.85)
Hemoglobin, g/l	115.3 (56.0–177.0)
Platelets, ×10⁹ cells/l	156.3 (4.0–503.0)
LMR	2.57 (0.39–7.0)
≤2.22	49.4% (86/174)
>2.22	50.6% (88/174)
3-Month mortality rate, %	59.2% (103/174)
6-Month mortality rate, %	74.1% (129/174)
Child-Pugh grade
0	20.7% (36/174)
1	44.8% (78/174)
2	34.5% (60/174)
TNM stage
I	9.8% (17/174)
II	11.5% (20/174)
III	56.3% (98/174)
IV	22.4% (39/174)
Lymph node metastasis	30.5% (53/174)
Distant metastases	20.7% (36/174)
Portal vein thrombosis	72.4% (126/174)
NCCN-TNM
T1	10.9% (19/174)
T2	13.8% (24/174)
T3-T4	75.3% (131/174)

ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte-to-monocyte ratio; NCCN, National Comprehensive Cancer Network; TNM, tumor-node-metastasis.

Table II.

Independent prognostic factors for overall survival in patients with hepatitis B virus-associated advanced hepatocellular carcinoma according to univariate and multivariate analysis.

	Univariate analysis			Multivariate analysis

Variables	HR	95% CI	P-value	HR	95% CI	P-value
Age	0.983	0.971–0.996	0.009
Leukocytes, ×10⁹ cells/l	1.085	1.042–1.130	0.000
Neutrophils, ×10⁹ cells/l	1.130	1.077–1.186	0.000	1.104	1.046–1.165	0.000
AMC, ×10⁹ cells/l	1.348	1.013–1.794	0.040
ALC, ×10⁹ cells/l	0.832	0.613–1.129	0.237
LMR	0.765	0.675–0.867	0.000	0.858	0.754–0.976	0.020
Platelets, ×10⁹ cells/l	1.002	1.001–1.004	0.006
AST, U/l	1.001	1.000–1.001	0.000
AFP, ng/dl, >400 vs. ≤400	2.30	1.649–2.309	0.000	1.739	1.221–2.478	0.002
Ascites, yes vs. no	2.05	1.444–2.909	0.000
Tumor number, <3 vs. ≥3	1.306	1.106–1.542	0.002
Tumor size, cm, <1 vs. ≥1	3.450	1.682–7.077	0.001
PVTT, yes vs. no	2.661	1.792–3.951	0.000	1.984	1.296–3.037	0.002

HR, hazard ratio; CI, confidence interval; ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte-to-monocyte ratio; AST, aspartate transaminase; ALP, alkaline phosphatase; AFP, α-fetoprotein; PVTT, portal vein tumor thrombus.

Table III.

Clinical features between the high and low LMR groups.

	LMR

Characteristics	≤2.22 (n=86)	>2.22 (n=88)	P-value
Age, years	54.4±4.51	56.8±13.2	0.217
Sex
Male	76	81	0.415
Female	10	7
Leukocytes, ×10⁹ cells/l	8.0±4.3	5.7±2.1	0.000
Neutrophils, ×10⁹ cells/l	6.1±3.5	3.7±1.8	0.000
Monocytes, ×10⁹ cells/l	0.8±0.6	0.4±0.2	0.000
Lymphocytes, ×10⁹ cells/l	1.1±0.6	1.4±0.5	0.000
Platelets, ×10⁹ cells/l	164.1±109.4	148.7±95.0	0.584
Hemoglobin, g/l	112.3±21.7	118.3±21.7	0.068
AST, U/l	266.4±323.9	164.6±200.8	0.002
Total bilirubin, µmol/l	105.2±136.7	72.6±108.0	0.002
Albumin, g/l	32.0±6.3	33.9±6.1	0.045
ALP, U/l	212.7±144.2	148.3±76.1	0.006
BUN, mmol/l	6.8±4.2	6.1±3.2	0.546
Creatinine, µmol/l	75.2±30.2	76.4±27.6	0.137
AFU, U/l	30.3±17.4	29.7±18.5	0.758
GGT, U/l	292.9±268.4	215.3±179.7	0.091
Prothrombin time, sec	70.6±18.1	75.4±19.5	0.088
INR	1.3±0.3	1.3±0.3	0.125
Lymph node metastasis
Absent	54	67	0.056
Present	32	21
Distant metastasis
Absent	60	78	0.002
Present	36	0
PVTT
Absent	18	30	0.052
Present	68	58
Tumor number
≤3	34	43	0.215
>3	52	45
Tumor size, cm
<2	12	28	0.005
≥2	74	60
Ascites
Absent	15	44	0.000
Present	71	44
3-Month survival rate, %	25.6 (22/86)	55.7 (49/88)	0.000
6-Month survival rate, %	14.0 (12/86)	37.5 (33/88)	0.000

LMR, leukocyte-to-monocyte ratio; AST, aspartate transaminase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; AFU, α-L-fucosidase; GGT, γ-glutamyl transpeptidase; PVTT, portal vein tumor thrombus; INR, international normalized ratio.